A pharmaceutical formulation comprising desvenlafaxine having an MMD of betweenabout 5µm and about 100µm, or a pharmaceutically acceptable saltthereof, and at least one matrix rate-controlling pharmaceutically acceptablepolymer, solid unit dosage form containing it, methods for preparing such a formulationand for its use to treat depression and related disorders and diseases.
